-transparent.png){kind=logo}
Neonatal administration of monosodium glutamate (MSG) failed to alter blood pressure (BP) development in either SHR or WKY rats. Hypothalamic disturbance relevant to hypertension in the SHR is not contributed to by neonatal MSG treatment. All normotensive WKY animals show a transient rise in BP corresponding to the time at which BP peaks in SHR.
Related Publications
J W Hambley, and
G A Johnston, and
L J Rogers
January 1991,
Clinical and experimental hypertension. Part A, Theory and practice,
J W Hambley, and
G A Johnston, and
L J Rogers
January 1988,
Clinical and experimental hypertension. Part A, Theory and practice,
J W Hambley, and
G A Johnston, and
L J Rogers
February 1998,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J W Hambley, and
G A Johnston, and
L J Rogers
January 1995,
Fundamental & clinical pharmacology,
J W Hambley, and
G A Johnston, and
L J Rogers
November 1994,
Clinical and experimental pharmacology & physiology,
J W Hambley, and
G A Johnston, and
L J Rogers
March 1985,
Brain research,
J W Hambley, and
G A Johnston, and
L J Rogers
January 1991,
Clinical and experimental hypertension. Part A, Theory and practice,
J W Hambley, and
G A Johnston, and
L J Rogers
March 1980,
The American journal of physiology,
J W Hambley, and
G A Johnston, and
L J Rogers
January 1984,
Clinical and experimental hypertension. Part A, Theory and practice,
J W Hambley, and
G A Johnston, and
L J Rogers
December 1990,
Journal of cardiovascular pharmacology,
